---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-26-000079"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2026-07-08T13:03:46+00:00"
generated_at: "2026-07-08T13:05:06.249518+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evolus licenses Profhilo for U.S. skin-quality market; no upfront payment

## Summary
- Exclusive license to develop and commercialize Profhilo in the U.S. for aesthetics and dermatology.
- No upfront or milestone payments; economics via transfer-price model supporting target gross margins.
- Evolus responsible for U.S. development and FDA approval; initial term 15 years from first approval.
- Profhilo has 4.8M+ treatments globally since 2015; market leader in European injectable skin quality.
- Agreement does not affect 2026 revenue/opex/operating profit outlook or 2028 targets.

## SEC filing metadata
- accession: 0001570562-26-000079
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2026-07-08T13:03:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/0001570562-26-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/eols-20260707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-26-000079
- JSON: https://secwatch.observer/filing/0001570562-26-000079.json
- Plain text: https://secwatch.observer/filing/0001570562-26-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.